Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997776294> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W1997776294 endingPage "A180" @default.
- W1997776294 startingPage "A180" @default.
- W1997776294 abstract "It is currently estimated that 2 million South Africans suffer from Type 2 Diabetes. Experts agree that the burden of diabetes is unacceptably high. Thus access to appropriate treatment is a priority for the country. The objective of this study was to investigate the cost effectiveness of saxagliptin (Onglyza®), a DPP-4 inhibitor, plus metformin compared with a sulphonylurea (SU) plus metformin (MET) in South African patients not well controlled on metformin alone. Data from a 52 week clinical trial comparing saxagliptin and sulphonylurea in combination with metformin was used in a simulation model to estimate long term complications in a cohort of type 2 diabetes patients. The model estimates the incidence of microvascular and macrovascular complications, diabetes-specific mortality, all-cause mortality, and ultimately, costs and quality-adjusted life years (QALYs) associated with the investigated treatment strategies. Costs and QALYs were estimated for a lifetime time horizon and discounted at 5%. The perspective of private health care funders was used. Compared with SU+ MET, the cost per QALY gained with saxagliptin+MET is approximately ZAR 35,566. Patients on saxagliptin+MET gain 0.1 QALYs on average when compared to SU+ MET, at an incremental cost of around ZAR 3775. The cost-effectiveness results were robust to various sensitivity analyses. The improvement in quality of life was associated mainly with lower incidence of hypoglycaemic events and modest reductions in both macro and micro vascular complications in the cohort receiving saxagliptin plus metformin compared with SU+MET. This study demonstrates that, over a patient's lifetime, the addition of saxagliptin to metformin is associated with improvements in quality-adjusted life years compared with SU in patients with type 2 diabetes. Saxagliptin treatment is a cost-effective treatment alternative for type 2 diabetes in patients not well-controlled on metformin alone." @default.
- W1997776294 created "2016-06-24" @default.
- W1997776294 creator A5002972113 @default.
- W1997776294 creator A5007186254 @default.
- W1997776294 creator A5037827547 @default.
- W1997776294 creator A5038311456 @default.
- W1997776294 creator A5058915530 @default.
- W1997776294 date "2012-06-01" @default.
- W1997776294 modified "2023-09-30" @default.
- W1997776294 title "PDB53 Cost-Effectiveness of Saxagliptin (Onglyza®) in Type 2 Diabetes in South Africa" @default.
- W1997776294 doi "https://doi.org/10.1016/j.jval.2012.03.974" @default.
- W1997776294 hasPublicationYear "2012" @default.
- W1997776294 type Work @default.
- W1997776294 sameAs 1997776294 @default.
- W1997776294 citedByCount "0" @default.
- W1997776294 crossrefType "journal-article" @default.
- W1997776294 hasAuthorship W1997776294A5002972113 @default.
- W1997776294 hasAuthorship W1997776294A5007186254 @default.
- W1997776294 hasAuthorship W1997776294A5037827547 @default.
- W1997776294 hasAuthorship W1997776294A5038311456 @default.
- W1997776294 hasAuthorship W1997776294A5058915530 @default.
- W1997776294 hasBestOaLocation W19977762941 @default.
- W1997776294 hasConcept C112930515 @default.
- W1997776294 hasConcept C126322002 @default.
- W1997776294 hasConcept C134018914 @default.
- W1997776294 hasConcept C2524010 @default.
- W1997776294 hasConcept C2777180221 @default.
- W1997776294 hasConcept C2779284873 @default.
- W1997776294 hasConcept C2780282729 @default.
- W1997776294 hasConcept C2780323712 @default.
- W1997776294 hasConcept C3019080777 @default.
- W1997776294 hasConcept C33923547 @default.
- W1997776294 hasConcept C555293320 @default.
- W1997776294 hasConcept C61511704 @default.
- W1997776294 hasConcept C64332521 @default.
- W1997776294 hasConcept C71924100 @default.
- W1997776294 hasConcept C72563966 @default.
- W1997776294 hasConceptScore W1997776294C112930515 @default.
- W1997776294 hasConceptScore W1997776294C126322002 @default.
- W1997776294 hasConceptScore W1997776294C134018914 @default.
- W1997776294 hasConceptScore W1997776294C2524010 @default.
- W1997776294 hasConceptScore W1997776294C2777180221 @default.
- W1997776294 hasConceptScore W1997776294C2779284873 @default.
- W1997776294 hasConceptScore W1997776294C2780282729 @default.
- W1997776294 hasConceptScore W1997776294C2780323712 @default.
- W1997776294 hasConceptScore W1997776294C3019080777 @default.
- W1997776294 hasConceptScore W1997776294C33923547 @default.
- W1997776294 hasConceptScore W1997776294C555293320 @default.
- W1997776294 hasConceptScore W1997776294C61511704 @default.
- W1997776294 hasConceptScore W1997776294C64332521 @default.
- W1997776294 hasConceptScore W1997776294C71924100 @default.
- W1997776294 hasConceptScore W1997776294C72563966 @default.
- W1997776294 hasIssue "4" @default.
- W1997776294 hasLocation W19977762941 @default.
- W1997776294 hasOpenAccess W1997776294 @default.
- W1997776294 hasPrimaryLocation W19977762941 @default.
- W1997776294 hasRelatedWork W1963999135 @default.
- W1997776294 hasRelatedWork W2002269706 @default.
- W1997776294 hasRelatedWork W2073314743 @default.
- W1997776294 hasRelatedWork W2168411651 @default.
- W1997776294 hasRelatedWork W2473991910 @default.
- W1997776294 hasRelatedWork W3130171081 @default.
- W1997776294 hasRelatedWork W3199440069 @default.
- W1997776294 hasRelatedWork W4240861382 @default.
- W1997776294 hasRelatedWork W4253947007 @default.
- W1997776294 hasRelatedWork W2189353858 @default.
- W1997776294 hasVolume "15" @default.
- W1997776294 isParatext "false" @default.
- W1997776294 isRetracted "false" @default.
- W1997776294 magId "1997776294" @default.
- W1997776294 workType "article" @default.